Trials / Recruiting
RecruitingNCT06055816
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Endostar and Envafolimab | Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy. |
Timeline
- Start date
- 2023-09-28
- Primary completion
- 2024-09-30
- Completion
- 2028-06-30
- First posted
- 2023-09-28
- Last updated
- 2023-09-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06055816. Inclusion in this directory is not an endorsement.